As a longtime tech analyst and investor, I've learned that tracking unstoppable trends is a great way to make money.
For instance, the mobile wave is moving so fast it's turning small-cap companies into financial juggernauts, seemingly overnight.
The same thing is happening with cloud computing. Simply put, there's a stampede of firms that want to host their data and applications on the web – and are willing to pay top dollar for those services.
But, strictly speaking, not every big-gain opportunity is a true high-tech trend.
That's why I always keep a sharp eye out for new investing opportunities that are in related areas.
The mid-cap company I'm recommending today, for example, is a leader in what I call personal defense technology.
And it's about to "outgun" the market – big time…
Hitting the Bull's Eye
The political views are wide-ranging on this one. But when you look strictly through the lens of an investor, the storied firm we're going to cover today consistently hits the bull's eye. And, as Money Morning's defense analyst, it's my job to let you know…
Fact is, there are millions of sportsmen out there who, like me, like to spend their weekends in amateur events like shooting trap. It's one of several shooting events for which one can win an Olympic medal.
No, I don't have any illusions that I'll get that good…
But I will say this: Shooting trap has definitely made me a better investor.
And the reason is simple.
You just cannot do well in a sport like this unless you learn how to block out all the distractions around you.
Consider that in trap you stand at least 16 yards from a short "house" that throws out targets the size of compact discs at about 45 miles per hour. Not only are the clay pigeons flying away from you at high speeds, but they often move at sharp angles that are hard to track.
Hitting those fast-moving targets requires the same skill you need to make money investing in stocks – you absolutely have to focus with laser-like precision.
So, I'm happy to report that my philosophy stood me in good stead a few weekends ago when I won a trap-shooting contest at my local northern California range, the Martinez Gun Club.
Just as I do with studying the markets every day, I had to filter out a lot of noise, including some loud spectators excited about the intense duel unfolding before them.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.